复星医药(600196.SH)控股子公司获美国FDA药品临床试验批准

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotech Co., Ltd., has received FDA approval to conduct Phase I clinical trials for HLX43, a targeted PD-L1 antibody-drug conjugate for thymic carcinoma treatment [1] Group 1 - The new drug HLX43 is a conjugate developed by linking a novel DNA topoisomerase I inhibitor with a self-developed PD-L1 targeting antibody [1] - The company plans to conduct global multi-center clinical research in Australia, Japan, and the United States once conditions are met [1] - HLX43 is intended for the treatment of advanced/metastatic solid tumors [1]